Cidara Therapeutics, Inc.
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
About
CEO
Dr. Jeffrey L. Stein Ph.D.
Employees
69
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
6310 Nancy Ridge Drive, San Diego, CA 92121, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | — | — | — | — |
| Aug 12, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Apr 22, 2025 | — | — | — | — |
| Nov 8, 2024 | -4.25 | -2.45 | 1.80 | -42.35% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 4 |
| Average estimate | — | -3.26 | — | -8.58 |
| Low estimate | — | -5.13 | — | -14.39 |
| High estimate | — | -1.27 | — | -4.80 |
| Last year EPS | — | -2.28 | — | -22.94 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-359.060%
Next qtr. (Mar 2025)
-42.980%
Current year
-341.060%
Next year (Dec 2025)
62.600%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 63.91M | 64.45M | 49.57M | 12.07M | 20.92M |
| Cost of revenue | 1.52M | — | — | — | — |
| Gross profit | 62.38M | 64.45M | — | — | — |
| Operating expense | |||||
| Research & development | 68.53M | 77.41M | 73.09M | 68.02M | 46.40M |
| Selling general and admin | 18.33M | 20.55M | 18.74M | 15.90M | 16.24M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -24.48M | -33.50M | -42.26M | -71.85M | -41.72M |
| Non operating interest income | |||||
| Income | 2.00M | 191,000 | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | — | — | — | — | 411,000 |
| Pretax income | -22.49M | -33.31M | -42.47M | -72.11M | -41.09M |
| Tax provision | 443,000 | 272,000 | — | — | — |
| Net income | -22.93M | -33.58M | -42.47M | -72.11M | -41.09M |
| Basic EPS | -5.20 | -8.60 | -16.20 | -36.00 | -28.20 |
| Diluted EPS | -5.20 | -8.60 | -16.20 | -36.00 | -28.20 |
| Basic average shares | 4.37M | 3.49M | 2.62M | 2.08M | 1.45M |
| Diluted average shares | 4.37M | 3.49M | 2.62M | 2.08M | 1.45M |
| EBITDA | -24.37M | -33.36M | -42.26M | -70.80M | -42.14M |
| Net income from continuing op. | -22.93M | -33.58M | -42.47M | -72.11M | -41.09M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 67.03M | 47.49M | 75.33M | 60.42M | 68.98M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 35.78M | 32.73M | 59.68M | 35.91M | 50.27M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 16.25M | 5.83M | 5.36M | 11.18M | 10,000 |
| Other receivables | — | — | — | — | — |
| Inventory | 6.10M | — | — | — | — |
| Prepaid assets | — | 6.53M | 4.07M | 3.07M | 5.54M |
| Restricted cash | — | — | 2.59M | 7.04M | 10.00M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 2.73M | 6.53M | — | — | — |
| Non current assets | |||||
| Properties | 7.39M | 3.51M | 4.66M | 3.17M | 3.74M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 505,000 | 540,000 | 686,000 | 665,000 | 742,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 425,000 | 425,000 | 425,000 | 425,000 | 425,000 |
| Accumulated depreciation | -3.19M | -3.16M | -3.22M | -3.05M | -2.84M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 1.05M | 1.07M | 1.08M | 2.02M | 1.10M |
| Total liabilities | 75.24M | 61.93M | 53.75M | 49.71M | 31.14M |
| Current liabilities | |||||
| Accounts payable | 3.77M | 1.45M | 1.30M | 4.57M | 1.89M |
| Accrued expenses | 14.18M | 7.67M | 10.20M | 7.96M | 4.07M |
| Short term debt | 1.30M | 1.21M | 3.74M | 7.96M | 10.78M |
| Deferred revenue | 25.10M | 14.61M | 13.92M | 13.87M | 9.80M |
| Tax payable | 18.04M | 11.53M | — | — | — |
| Pensions | 5.03M | 4.92M | 4.86M | 4.21M | 3.66M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 3.58M | — | 1.32M | — | 942,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 9,000 | 7,000 | 7,000 | 4,000 | 3,000 |
| Retained earnings | -441.43M | -418.50M | -377.17M | -334.70M | -259.83M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | -8.21M | -14.44M | 21.57M | 10.72M | 37.84M |
| Additional paid in capital | 433.21M | 404.06M | 398.73M | 345.41M | 297.66M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -22.93M | -33.58M | -42.47M | -72.11M | -41.09M | -59.02M | -55.73M | -48.17M | -32.19M | -11.89M | -1.34M |
| Depreciation | 118,000 | 143,000 | -1.23M | 1.05M | -1.39M | 523,000 | 667,000 | 732,000 | 461,000 | 179,000 | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 3.06M | 3.53M | 4.01M | 4.09M | 5.07M | 5.71M | 5.71M | 4.34M | 3.03M | 232,000 | 11,000 |
| Other Non-Cash Items | 1.24M | 982,000 | 15,000 | 21,000 | 36,000 | 86,000 | 50,000 | 14,000 | 76,000 | 1.91M | 262,000 |
| Accounts Receivable | -10.41M | -477,000 | 5.82M | -11.17M | -10,000 | 321,000 | — | — | — | — | — |
| Accounts Payable | 8.89M | -2.37M | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -12.63M | 1.80M | 9.94M | 15.43M | 13.15M | -1.08M | 67,000 | 1.53M | 1.05M | 222,000 | — |
| Operating Cash Flow | -32.67M | -29.98M | -23.91M | -62.68M | -24.23M | -53.46M | -49.23M | -41.55M | -27.57M | -9.35M | -1.07M |
| Investing Activities | |||||||||||
| Capital Expenditures | -505,000 | -118,000 | -41,000 | -186,000 | -35,000 | -177,000 | -306,000 | -401,000 | -1.17M | -991,000 | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | -14.55M | -19.52M | -69.62M | -54.92M | — | — |
| Sale of Investments | — | — | — | — | — | 29.03M | 24.30M | 95.50M | 10.00M | — | — |
| Investing Cash Flow | -505,000 | -118,000 | -41,000 | -186,000 | -35,000 | 14.30M | 4.47M | 25.48M | -46.09M | -991,000 | — |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | 9.95M | — | 930,000 | 1.23M |
| Long-Term Debt Payments | — | -2.59M | -4.44M | -2.96M | — | — | — | — | — | — | — |
| Other Financing Charges | — | -720,000 | — | — | -31,000 | 49.51M | — | — | — | -233,000 | — |
| Financing Cash Flow | 25.96M | -951,000 | 44.59M | 34.30M | 14.27M | 55.95M | 20.66M | 36.57M | 111.43M | 30.56M | 1.23M |
| Other Cash Details | |||||||||||
| End Cash Position | 35.78M | 32.73M | 62.27M | 42.95M | 60.27M | 74.56M | 60.81M | 85.37M | 62.56M | 22.80M | 185,000 |
| Income Tax Paid | 797,000 | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | 40,000 | 228,000 | 445,000 | 616,000 | 582,000 | 511,000 | — | — | — | — |
| Free Cash Flow | -22.94M | -28.59M | -25.27M | -54.60M | -28.57M | -56.88M | -50.22M | -40.17M | -27.13M | -8.70M | -1.05M |
Error: Invalid format in Holders JSON file.
Article
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Jan 30, 2025
Article
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Dec 3, 2024
Article
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effective in immunocompromised patients, and could revolutionize flu treatment. The global influenza vaccine market is projected to grow to $17.77 billion by 2032.
Nov 21, 2024
